Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses To Recall Product, USA

At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient.

More: continued here

Filed under: Medical Malpractice / Litigation on July 25th, 2008